Patents by Inventor Michel Canavaggio

Michel Canavaggio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor VIIa-polysialic acid conjugates having prolonged in vivo half-life
    Patent number: 10251941
    Abstract: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: April 9, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Turecek, Juergen Siekmann, Friedrich Scheiflinger, Michel Canavaggio
  • FACTOR VIIA-POLYSIALIC ACID CONJUGATES HAVING PROLONGED IN VIVO HALF-LIFE
    Publication number: 20160129121
    Abstract: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
    Type: Application
    Filed: November 19, 2015
    Publication date: May 12, 2016
    Inventors: Peter Turecek, Juergen Siekmann, Friedrich Scheiflinger, Michel Canavaggio
  • FACTOR VIIA-POLYSIALIC ACID CONJUGATES HAVING PROLONGED IN VIVO HALF-LIFE
    Publication number: 20140186323
    Abstract: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 3, 2014
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: Peter Turecek, Juergen Siekmann, Friedrich Scheiflinger, Michel Canavaggio
  • Factor VIIa-Polysialic Acid Conjugate Having Prolonged In Vivo Half-Life
    Publication number: 20080221032
    Abstract: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
    Type: Application
    Filed: December 14, 2007
    Publication date: September 11, 2008
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Peter Turecek, Juergen Siekmann, Friedrich Scheiflinger, Michel Canavaggio, Marie Christine Canavaggio